Congratulations to our client Acadia Pharmaceuticals Inc. for appointing Scott Cenci as Chief Information and Data Officer.
Acadia is a biopharmaceutical company dedicated to advancing breakthroughs in neurological and rare diseases to improve and elevate lives. Since its founding, Acadia has operated at the forefront of healthcare, delivering vital solutions to those who need them most. The company developed and commercialized the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only approved therapy in the United States and Canada for Rett syndrome. Acadia’s clinical-stage pipeline includes programs for Prader-Willi syndrome, Alzheimer’s disease psychosis, and multiple additional initiatives targeting neuroscience and neuro-rare disorders.
C1 Team: Tom Barnes, Tom Murphy, & James Reynolds